Located in the heart of Europe & EU
Our headquarters is based in central Poland, 1.5 hours’ drive from the Warsaw airport. As one would anticipate from an EU based CDMO, we guarantee the highest levels of production and analytics standards for your business. Additionally, our “can-do” approach to our clients’ needs offers solutions to unforeseen challenges which we overcome as a team.
Read what’s happening at Mabion’s.
Another win for antibody-drug conjugates in breast cancer
Another win for antibody-drug conjugates in breast cancer The results of the pivotal efficacy trial of sacituzumab govitecan, an innovative antibody-drug conjugate developed by Gilead Sciences, have just been published in The Lancet, showing improved survival of HR-positive, EGFR2-negative breast cancer patients receiving the new drug. In this trial, 543 subjects were randomized to treatment […]
Updated Novavax’s COVID vaccine effectively neutralizes…
Updated Novavax’s COVID vaccine effectively neutralizes newly emerging SARS-CoV-2 variants The updated Novavax’s COVID-19 vaccine has been reported to effectively neutralize EG.5.1 and XBB.1.16.6 subvariants, which were designated as variants of interest (VOIs) by WHO and are currently circulating all over the globe (majority of COVID cases in the EU and US are now EG.5.1 […]
Market welcomes the arrival of new RSV vaccines
Market welcomes the arrival of new RSV vaccines Pfizer has announced positive decision of FDA on the approval of its protein RSV vaccine for older adults. The product is expected to be launched before the arrival of the next RSV season this winter (third quarter). After the COVID-19 pandemic and long-term isolation from various pathogens, […]
Mabion signs contract to purchase new bioreactors…
Mabion signs contract to purchase new bioreactors diversifies technology and opens to new customers On July 11th, 2023, Mabion concluded an agreement with Global Life Sciences Solutions Polands Sp. z o.o., a Cytiva group company for the purchase of a set of Xcellerex XDR bioreactors with conventional mixing technology. The contract is valued at EUR […]